Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research

Abstract

Background Finding new therapeutic uses for existing medicines could lead to safe, affordable and timely new treatment options for patients with high medical needs. However, due to a lack of economic incentives, pharmaceutical developers are rarely interested to invest in research with approved medicines, especially when they are out of basic patent or regulatory protection. Consequently, potential new uses for these medicines are mainly studied in independent clinical trials initiated and led by researchers from academia, research institutes, or collaborative groups. Yet, additional financial support is needed to conduct expensive phase III clinical trials to confirm the results from exploratory research. Methods In this study, scientific and grey literature was searched to identify and evaluate new mechanisms for funding clinical trials with repurposed medicines. Semi-structured interviews were conducted with 16 European stakeholders with expertise in clinical research, funding mechanisms and/or drug repurposing between November 2018 and February 2019 to consider the future perspectives of applying new funding mechanisms. Results Traditional grant funding awarded by government and philanthropic organisations or companies is well known and widely implemented in all research fields. In contrast, only little research has focused on the application potential of newer mechanisms to fund independent clinical research, such as social impact bonds, crowdfunding or public-private partnerships. Interviewees stated that there is a substantial need for additional financial support in health research, especially in areas where there is limited commercial interest. However, the implementation of new funding mechanisms is facing several practical and financial challenges, such as a lack of expertise and guidelines, high transaction costs and difficulties to measure health outcomes. Furthermore, interviewees highlighted the need for increased collaboration and centralisation at a European and international level to make clinical research more efficient and reduce the need for additional funding. Conclusions New funding mechanisms to support clinical research may become more important in the future but the unresolved issues identified in the current study warrant further exploration.

Drug Repurposing for Rare Diseases: A Role for Academia

“…In addition, the strength of second-use patents to protect against competitors is often weak ( Pushpakom et al, 2018 ; Verbaanderd et al, 2020 ). Second, additional costly clinical development investments may be needed to prove efficacy for the new indication, as well as possible additional requirements with respect to dosing and safety ( Kort & Jovinge., 2021 ; Verbaanderd et al, 2021 ). These additional costs may limit the prospects for sufficient profitability, especially when low-priced generic versions of the originator are already used off-label ( Breckenridge & Jacob., 2018 ; Verbaanderd et al, 2020 ).…”

An overview of Fintech applications to solve the puzzle of health care funding: state-of-the-art in medical crowdfunding

“…An alternative funding perspective and an altered private–public mix in the financing of R&D may bring new life to a number of compounds in different disease areas (e.g. different types of cancer, Parkinson’s disease), which are currently deprioritized because of their poor commercial prospects (Verbaanderd et al 2021 ).…”

Impact of COVID-19 Pandemic Declaration on New Oncology Trial Commencements: An Interrupted Time Series with Segmented Regression Analysis

“…In addition, study types, such as interventional or observational studies, might be different depending on the funding source, and trend changes based on study types were not observed when comparing pre- and postpandemic periods in the current analysis. Although Gresham et al reported a decline in NIH-funded trials from 2005 to 2015 [ 5 ], during the COVID-19 pandemic, government-funded medical research bodies in many countries were reported to maintain funding continuity for research studies [ 32 ]. Such an increase in the allocation of funds could influence the number of new oncology trials launched during the COVID-19 pandemic.…”